West Pharma earnings make the case it is more than a GLP-1 play, and the setup still has upside. If the GLP-1 narrative stops driving the stock, the core business can carry the multiple.

What happened: West Pharmaceutical Services reported earnings, and CNBC said the results show the company is more than a GLP-1 play. CNBC expects further upside for the stock. Key numbers: Shares have gained around 20% since CNBC highlighted the stock's attractive valuation in August. Why it matters: CNBC sees more upside ahead for the stock after the earnings report.

West Pharmaceutical Services reported earnings, and CNBC said the results show the company is more than a GLP-1 play. CNBC expects further upside for the stock.

CNBC sees more upside ahead for the stock after the earnings report.